FTSE MIB
34.249,77 +310,02 (+0,91%) Dow Jones
38.239,66 +153,86 (+0,40%) Nasdaq
15.927,90 +316,14 (+2,03%) Nikkei 225
37.934,76 +306,28 (+0,81%) Petrolio
83,66 +0,09 (+0,11%) Bitcoin EUR
59.653,45 +846,49 (+1,44%)
Oryzon Genomics S.A. (0RDB.L)
| Chiusura precedente | 1,9800 |
| Aperto | 1,9740 |
| Denaro | 0,0000 x 0 |
| Lettera | 0,0000 x 0 |
| Min-Max giorno | 1,9740 - 2,0000 |
| Intervallo di 52 settimane | 1,6020 - 2,3950 |
| Volume | |
| Media Volume | 2.518 |
| Capitalizzazione | 730.746 |
| Beta (5 anni mensile) | 0,64 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -0,0880 |
| Prossima data utili | N/D |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
GlobeNewswireORYZON presents blinded aggregate safety data from vafidemstat’s ongoing Phase IIb PORTICO trial in Borderline Personality Disorder
At the 36th European College of Neuropsychopharmacology congress (ECNP-2023) MADRID, Spain and BOSTON, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that the company presented an update on vafidemstat’s ongoing Phase IIb PORTICO trial in borderline personality disorder (BPD) at the 36th European College of Neu
- GlobeNewswire
ORYZON Receives Two Grants to Further Explore the Role of Epigenetic Targets in the Treatment of Neuronal Pathologies
Two collaborative projects with public research centers with a global budget of 2.3 million eurosOryzon to receive up to 1.4 million eurosFocused on the discovery and validation of novel biomarkers and epigenetic targets for the treatment of neuronal pathologies MADRID, Spain and BOSTON, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medica
- GlobeNewswire
ORYZON to Provide Corporate Progress Updates at Several Events in October
East-West Biopharma Summit 36th European College of Neuropsychopharmacology congress (ECNP 2023)Investor Access 2023 EventJefferies Inaugural Biotech CNS/Neuro Summit Roth Capital Partners 2nd Healthcare Opportunities Conference ESMO (European Society for Medical Oncology) 2023 congress MADRID, Spain and BOSTON, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases
